Skip Navigation


Annals of Oncology Advance Access originally published online on April 25, 2008
Annals of Oncology 2008 19(9):1523-1529; doi:10.1093/annonc/mdn169
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/9/1523    most recent
mdn169v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gravalos, C.
Right arrow Articles by Jimeno, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gravalos, C.
Right arrow Articles by Jimeno, A.
Related Collections
Right arrow 2008 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

reviews

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

C. Gravalos1,* and A. Jimeno2

1 Medical Oncology Department, University Hospital "12 de Octubre", Madrid, Spain
2 Developmental Therapeutics/Pharmacodynamic Laboratory, University of Colorado Cancer Center, Aurora, CO, 80045 USA

* Correspondence to: Dr C. Gravalos, Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Avda. de Andalucía s/n Km 5.400, 28041 Madrid, Spain. Tel: +34-91-390-83-49; Fax: +34-91-460-33-10; E-mail: cgravalos{at}telefonica.net

Gastric cancer is the second leading cause of cancer mortality in the world and its management, especially in advanced stages, has evolved relatively little. In particular, no targeted modality has so far been incorporated to its treatment armamentarium. HER2 overexpression is increasingly recognized as a frequent molecular abnormality, driven as in breast cancer by gene amplification. There is mounting evidence of the role of HER2 overexpression in patients with gastric cancer, and it has been solidly correlated to poor outcomes and a more aggressive disease. Additionally, preclinical data are showing significant antitumor efficacy of anti-HER2 therapies (particularly monoclonal antibodies directed towards the protein) in in vitro and in vivo models of gastric cancer. As a result, several clinical trials are exploring in different settings and with diverse designs the potential of anti-HER2 therapies in gastric cancer patients. This review summarizes the rationale, preclinical evidence, retrospective clinical analyses, and the interim clinical data pertaining HER2 therapies in gastric cancer.

Key words: c-ErbB-2, gastric cancer, gastroesophageal adenocarcinoma, HER2, prognostic factor, trastuzumab

Received for publication January 29, 2008. Revision received April 13, 2008. Accepted for publication March 20, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.